Get started
Author

Bogdana I Balas

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
2017 · Solange Peters, D. Ross Camidge, et al. · New England Journal of Medicine · 2,527
PDF
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015 · Alice T Shaw, Leena Gandhi, et al. · The Lancet Oncology · 638
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015 · Sai-Hong Ignatius Ou, Jin Seok Ahn, et al. · Journal of Clinical Oncology · 584
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
2019 · D. Ross Camidge, Rafal Dziadziuszko, et al. · Journal of Thoracic Oncology · 490
PDF
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer
2017 · James Chih-Hsin Yang, Sai-Hong Ignatius Ou, et al. · Journal of Thoracic Oncology · 83
Examining the safety of PPAR agonists – current trends and future prospects
2012 · Michele Bortolini, Matthew B Wright, et al. · Expert Opinion on Drug Safety · 75
Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.
2018 · D. Ross Camidge, Solange Peters, et al. · Journal of Clinical Oncology · 62
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
2019 · Maurice Pérol, Nick Pavlakis, et al. · Lung Cancer · 49
PDF
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects
2016 · Peter N. Morcos, Elena Guerini, et al. · Clinical Pharmacology in Drug Development · 49
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
2017 · Peter N. Morcos, Katrijn Bogman, et al. · Cancer Chemotherapy and Pharmacology · 38
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
2019 · Sai-Hong Ignatius Ou, Shirish M. Gadgeel, et al. · Lung Cancer · 31
Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
2015 · Sai-Hong Ignatius Ou, Jin Seok Ahn, et al. · Journal of Clinical Oncology · 31
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
2018 · Peter N. Morcos, Eveline Nueesch, et al. · Cancer Chemotherapy and Pharmacology · 30
PDF
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
2018 · Peter N. Morcos, Yumi Cleary, et al. · The Journal of Clinical Pharmacology · 28
PDF
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
2017 · Alice Tsang Shaw, Solange Peters, et al. · Journal of Clinical Oncology · 25
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).
2015 · Leena Gandhi, Alice Shaw, et al. · Journal of Clinical Oncology · 21
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
2021 · Joy C. Hsu, Felix Jaminion, et al. · CPT Pharmacometrics & Systems Pharmacology · 16
PDF
Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.
2016 · Joy C. Hsu, Ronan Carnac, et al. · Journal of Clinical Oncology · 16
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
2017 · D. Ross Camidge, Shirish Gadgeel, et al. · Journal of Thoracic Oncology · 11
PDF
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)
2023 · Sanna Iivanainen, Anne-Marie Baird, et al. · BMJ Open · 8
PDF
Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
2019 · Rucha J. Mehta, Amalia Gastaldelli, et al. · International Journal of Molecular Sciences · 8
PDF
Population pharmacokinetics (popPK) and exposure-response (ER) analyses bridge J-ALEX to the global population with an alectinib (ALC) 600mg bid dosing regimen.
2017 · Joy C. Hsu, Felix Jaminion, et al. · Journal of Clinical Oncology · 7
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
2017 · Alice Tsang Shaw, Solange Peters, et al. · Journal of Clinical Oncology · 6
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
2018 · Sai-Hong Ignatius Ou, Leena Gandhi, et al. · Journal of Clinical Oncology · 5
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
2021 · Nicolas Frey, Walter Bordogna, et al. · Clinical Pharmacology & Therapeutics · 3
PDF
Works count: 37
Citation count: 4,849
H-index: 16
I10-index: 19
Year
Topic
Type